Let’s be clear, people who choose alternative therapies over conventional cancer treatments have a greater risk of death. Individual choices are respected, but let’s not unravel the many, many gains in oncology by evidence-based care.

It was an honor to present, on behalf of the co-investigators, the planned OS results from FLAURA2 ph III at #WCLC25. These results confirm a shift in our first-line practice for our EGFRm pts, marking the first time a study has achieved a significant benefit mOS of 4Y. #EGFR

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25

Staggered this wasn’t a plenary at #asco25 @ASCO OS benefit Minimal toxicity Cost effective Generalizable What a missed opportunity! Well done to all involved 👏

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

No chemotherapy appointments were cancelled in our unit due to industrial action. Nor was it ever considered. NSW government walks back claims of cancelled chemo appointments

Come and work at Concord 👏 0.8 FTE staff specialist medical oncologist in upper & lower GI & gynae cancer available 👏 Staff Specialist Medical Oncology Crgh Apply Via Ecredential

Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

🚨 YOUNG ONC WORKSHOP IS HAPPENING THIS MORNING🚨 🙌🏻 Join @zarnielwin @DrMarkNalder @DrTimSlattery @BrandonBZLau for great sessions not be missed ⏰ 8am Perth 🕰️ 9am Brisbane ⏰ 10am Sydney & Melb @MOGA_ORG @drjameslynam @AOParsonson @DrLizConnolly @nicolafoneil

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: https://t.co/fEAbVvLFj0

The crew at the annual @TOGAANZ Lung Cancer Preceptorship in Brisbane. My fave meeting of the year! 👏

Word of the day is ‘recrudescence’ (17th century): the return of something terrible after a time of reprieve.

Disheartening. Frustrating. Devastating. Patients unable to access immunotherapy via PBS for recurrent NSCLC due to once in a lifetime rule that is inconsistent w/ current standard of care. Communicating this to patients is hard. @MOGA_ORG pls keep advocating for change 🙏

Hi friend! Elmo loves you. And Elmo will remind you every day if you need him to. ❤️

Why are the pollies so special compared to the rest of the public service? NSW staff specialists (drs) have to take the cheapest of 3 fares quoted by the contracted govt travel agents no ifs, buts or any special consideration allowed. https://t.co/X0kMvDFLQD

Oncology MDT’s require the presence & expertise of all key specialities to review, discuss & formulate management plans for people with cancer presented at the meetings. They’re not MDT’s if any one of these specialties are absent.

Calling all Cancer ♋️ Care Clinicians (Medical/Nursing/Allied Health)! We need your help to improve coordination of Diet 🍇 🍱 and Exercise 🏃‍♀️ 🎾 services for Cancer Care in Australia 🇦🇺 https://t.co/NyJT2CtcJn

Great panel of speakers for the Sydney event 🌟

This time last week I was talking to fellow oncologists about not conflating every clinical outcome with our self-worth Obviously we do our best for each patient but we also tend to be our own harshest critics & judge ourselves more severely in hindsight Extend yourself grace

Presented at #ESMO24: The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months. Full trial results: https://t.co/xu1i252fK8

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: https://t.co/jxKervUdpR #ESMO24